Blue Water Vaccines Inc's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Blue Water Vaccines Inc's ROA in the second quarter of 2026?
Blue Water Vaccines Inc recorded a cumulative net loss of $-9 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -45.48%.

However, within the Healthcare sector 534 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3843, from total ROA ranking in the first quarter of 2026 at 4777.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-12.09 %	-20.85 %	-12.11 %	-68.14 %	-67.88 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-9	-9	-14	-51	-46
Return On Assets (TTM)	-45.48 %	-43.31 %	-67.88 %	-235.06 %	-142.48 %
BWV's Total Ranking	# 3843	# 4777	# 4643	# 4579	# 4642
Total Assets (TTM) in million	17	15	25	20	19
Seq. Total Assets Change	13.52 %	-41.38 %	28.21 %	3.04 %	2.2 %
Seq. Net Income Change	-	-	-	-	-

BWV's 5 Years Annual ROA >> Back to BWV Management Effectiveness >> Compare BWV ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 225
Sector	# 535
Overall	# 3843

Return On Assets Statistics
High	Average	Low
-43.44 %	-89.78 %	-236.2 %
(Mar 31 2026)		(Sep 30 2025)

Financial Statements
Blue Water Vaccines Inc's Assets	$ 17 million	BWV's Balance sheet
Blue Water Vaccines Inc's Income	$ -3 million	Quarterly BWV's Income Statement
BWV's Income by Division		See BWV's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	FY
Y / Y Total Assets Change	-10.09 %	-68.45 %	238.09 %	-	-
Total Assets in million	25	28	89	26	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-14	-59	-37	-13	0
Annual Return On Assets	-55.62 %	-209.15 %	-42.06 %	-51.01 %	-

BWV's 5 Years Annual ROA >> Back to BWV Management Effectiveness >> Compare BWV ROA to its Competitors

More Return On Assets Ratios
BWV's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BWV's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BWV's Competitors
Subscribers only: Roa for Blue Water Vaccines Inc's Suppliers
Subscribers only: Return On Assets for BWV's Customers

You may also want to know
BWV's Roi	BWV's Inventory Turnover Ratio	BWV's Growth Rates	BWV's Dividend Comparisons
	BWV's Profitability Ratios	BWV's Asset Turnover Ratio	BWV's Dividend Growth
BWV's Roe	BWV's Valuation Ratios	BWV's Financial Strength Ratios	BWV's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-12T06:26:33+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.